Toshimitsu Yamaoka Advanced Cancer Translational Research Institute Showa University Biography Publications Institution JoVE Articles Toshimitsu Yamaoka has not added a biography. If you are Toshimitsu Yamaoka and would like to personalize this page please email our Author Liaison for assistance. Publications and Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in Molecular Cancer Therapeutics. 01, 2019 | Pubmed ID: 30322949 Receptor Tyrosine Kinase-Targeted Cancer Therapy International Journal of Molecular Sciences. Nov, 2018 | Pubmed ID: 30404198 Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms International Journal of Molecular Sciences. Nov, 2017 | Pubmed ID: 29140271 Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation Molecular Cancer Research : MCR. Jul, 2017 | Pubmed ID: 28289161 Up-regulation of Syndecan-4 Contributes to TGF-β1-induced Epithelial to Mesenchymal Transition in Lung Adenocarcinoma A549 Cells Biochemistry and Biophysics Reports. Mar, 2016 | Pubmed ID: 28955801 Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation Molecular Cancer Therapeutics. Dec, 2016 | Pubmed ID: 27612490 Association of Pharmacokinetics and Pharmacogenomics with Safety and Efficacy of Gefitinib in Patients with EGFR Mutation Positive Advanced Non-small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Mar, 2016 | Pubmed ID: 26898617 Phase II Study of Concurrent Chemoradiotherapy with Carboplatin and Vinorelbine for Locally Advanced Non-small-cell Lung Cancer Molecular and Clinical Oncology. May, 2014 | Pubmed ID: 24772308 Evaluation of the Safety and Efficacy of Combination Chemotherapy with Vinorelbine and Platinum Agents for Patients with Non-small Cell Lung Cancer with Interstitial Lung Disease Anticancer Research. Dec, 2012 | Pubmed ID: 23225454 Relationship of Circulating Tumor Cells to the Effectiveness of Cytotoxic Chemotherapy in Patients with Metastatic Non-small-cell Lung Cancer Oncology Research. Month, 2012 | Pubmed ID: 23193919 [The Mechanisms of Resistance to EGFR-TKIs and Challenges to Overcome Resistance in EGFR Mutant Non-small Cell Lung Cancer] Gan to Kagaku Ryoho. Cancer & Chemotherapy. Jun, 2012 | Pubmed ID: 22705678 Myelosuppression Induced by Concurrent Chemoradiotherapy As a Prognostic Factor for Patients with Locally Advanced Non-small Cell Lung Cancer Oncology Letters. Sep, 2011 | Pubmed ID: 22866156 [A Case of Pulmonary Aspergilloma Concomitant with Allergic Bronchopulmonary Aspergillosis] Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society. May, 2011 | Pubmed ID: 21688647 Specific Epidermal Growth Factor Receptor Autophosphorylation Sites Promote Mouse Colon Epithelial Cell Chemotaxis and Restitution American Journal of Physiology. Gastrointestinal and Liver Physiology. Aug, 2011 | Pubmed ID: 21617115 Phase II Trial of the Combination of Carboplatin and Irinotecan in Elderly Patients with Small-cell Lung Cancer European Journal of Cancer (Oxford, England : 1990). Jun, 2011 | Pubmed ID: 21458256 Phase II Trial of Amrubicin and Carboplatin in Patients with Sensitive or Refractory Relapsed Small-cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Sep, 2011 | Pubmed ID: 21277039 Phase II Study of S-1, a Novel Oral Fluoropyrimidine, and Biweekly Administration of Docetaxel for Previously Treated Advanced Non-small-cell Lung Cancer Cancer Chemotherapy and Pharmacology. Apr, 2011 | Pubmed ID: 20556612 Are Levels of Pro-gastrin-releasing Peptide or Neuron-specific Enolase at Relapse Prognostic Factors After Relapse in Patients with Small-cell Lung Cancer? Lung Cancer (Amsterdam, Netherlands). Feb, 2011 | Pubmed ID: 20537424 The UGT1A1*28 Genotype and the Toxicity of Low-dose Irinotecan in Patients with Advanced Lung Cancer Oncology Research. Month, 2010 | Pubmed ID: 20377135 IL-17A and IL-17F Stimulate Chemokines Via MAPK Pathways (ERK1/2 and P38 but Not JNK) in Mouse Cultured Mesangial Cells: Synergy with TNF-alpha and IL-1beta American Journal of Physiology. Renal Physiology. Mar, 2010 | Pubmed ID: 20042461 [Chemotherapy-induced Myelosuppression and Treatment Efficacy in Extensive-stage Small Cell Lung Cancer] Gan to Kagaku Ryoho. Cancer & Chemotherapy. Nov, 2009 | Pubmed ID: 19920385 Induction Chemoradiotherapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer Oncology Reports. Nov, 2009 | Pubmed ID: 19787234 Combination Effect Between Bortezomib and Tumor Necrosis Factor Alpha on Gefitinib-resistant Non-small Cell Lung Cancer Cell Lines Anticancer Research. Jun, 2009 | Pubmed ID: 19528497 Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer Anticancer Research. May, 2009 | Pubmed ID: 19443395 Preventive and Therapeutic Effects of Imatinib in Wistar-Kyoto Rats with Anti-glomerular Basement Membrane Glomerulonephritis Kidney International. May, 2009 | Pubmed ID: 19242505 Patient Willingness to Undergo Chemotherapy and Thoracic Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Psycho-oncology. May, 2009 | Pubmed ID: 18942662 Transactivation of EGF Receptor and ErbB2 Protects Intestinal Epithelial Cells from TNF-induced Apoptosis Proceedings of the National Academy of Sciences of the United States of America. Aug, 2008 | Pubmed ID: 18701712 Patient Satisfaction with Sedation for Flexible Bronchoscopy Respirology (Carlton, Vic.). Sep, 2008 | Pubmed ID: 18513244 [Two Cases with Recurrent Non-small Cell Lung Cancer Successfully Treated with Cisplatin and S-1] Gan to Kagaku Ryoho. Cancer & Chemotherapy. Feb, 2008 | Pubmed ID: 18281776 Effectiveness of Intensive Follow-up After Response in Patients with Small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Feb, 2008 | Pubmed ID: 17900754 [Two Cases of Successfully Treated Invasive Pulmonary Aspergillosis Following Influenza Virus Infection] Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society. Apr, 2007 | Pubmed ID: 17491315 Regulation of Apoptosis During Homeostasis and Disease in the Intestinal Epithelium Inflammatory Bowel Diseases. May, 2006 | Pubmed ID: 16670531 Phase I Study of the Combination of Gemcitabine and Nedaplatin for Treatment of Previously Untreated Advanced Non-small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Jan, 2003 | Pubmed ID: 12499100 स्थापना और तीन Afatinib प्रतिरोधी फेफड़े Adenocarcinoma पीसी-9 सेल लाइन्स की विशेषता Afatinib की बढ़ती खुराक के साथ विकसित Toshimitsu Yamaoka1, Motoi Ohba1, Yuki Matsunaga2, Junji Tsurutani1, Tohru Ohmori3 1Advanced Cancer Translational Research Institute, Showa University, 2Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine JoVE 59473 Cancer Research एक 2-कदम खुराक-वृद्धि प्रक्रिया के साथ फेफड़ों ग्रंथिकर्कटता कोशिकाओं में इन विट्रो में EGFR-TKI और TKI से मुलाकात के लिए दोहरी प्रतिरोध की स्थापना Toshimitsu Yamaoka1, Motoi Ohba1, Satoru Arata1,2, Tohru Ohmori1 1Institute of Molecular Oncology, Showa University, 2Center for Biotechnology, Showa University JoVE 55967 Cancer Research
स्थापना और तीन Afatinib प्रतिरोधी फेफड़े Adenocarcinoma पीसी-9 सेल लाइन्स की विशेषता Afatinib की बढ़ती खुराक के साथ विकसित Toshimitsu Yamaoka1, Motoi Ohba1, Yuki Matsunaga2, Junji Tsurutani1, Tohru Ohmori3 1Advanced Cancer Translational Research Institute, Showa University, 2Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine JoVE 59473 Cancer Research
एक 2-कदम खुराक-वृद्धि प्रक्रिया के साथ फेफड़ों ग्रंथिकर्कटता कोशिकाओं में इन विट्रो में EGFR-TKI और TKI से मुलाकात के लिए दोहरी प्रतिरोध की स्थापना Toshimitsu Yamaoka1, Motoi Ohba1, Satoru Arata1,2, Tohru Ohmori1 1Institute of Molecular Oncology, Showa University, 2Center for Biotechnology, Showa University JoVE 55967 Cancer Research
